CA-4948
CA-4948 (AU-4948) is a novel potent, selective, orally bioavailable IRAK4 inhibitor; shows in vivo activity in TLR4-induced cytokine release model, exhibits dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models; a therapeutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4 signaling, induces tumor regression in an ABC-DLBCL xenograft model combined with Venetoclax.Blood Cancer Phase 1 Clinical (In Vitro) :IRAK4-IN-7 has anti-cancer and anti-inflammatory activities, it can be used for cancer and inflammatory diseases treatment.
Product Specifications
CAS Number
1801343-74-7
Product Name Alternative
CA 4948 | CA4948 | AU-4948 | AU 4948 | AU4948
Purity
>98% (HPLC)
Solubility
DMSO : 13.89 mg/mL 33.28 mM; H2O : < 0.1 mg/mL
Smiles
O=C (C1=CC=CC (C2=CC=C (N) N=C2) =N1) NC3=CN=C4C (OC (N5CCOCC5) =N4) =C3
Molecular Formula
C21H19N7O3
Molecular Weight
417.429
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
6'-amino-N- (2-morpholinooxazolo[4,5-b]pyridin-6-yl) -[2,3'-bipyridine]-6-carboxamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Interleukin 6, Recombinant, Human (Interleukin-6, IL6, IL-6, B Cell Stimulatory Factor 2, BSF2, BSF-2, CTL Differentiation Factor, CDF, Hybridoma Growth Factor, HGF, HSF, Interferon beta-2, IFN-beta-2, IFNB2)
Influenza A H5N1 (A/Egypt/N05056/2009) HA protein, His Tag
